TORONTO, ON / ACCESSWIRE / August 26, 2020 / Pelangio Exploration Inc. (TSXV:PX)(OTC PINK:PGXPF) ("Pelangio" or the "Company") is pleased to provide an update on its Dalton Project located in Timmins and its Grenfell Project located 10 kilometers ("km") northwest of Kirkland Lake Ontario.

Dalton Project

In late July, the Company completed 826 meters ("m") of diamond drilling in four drill holes to test two coincident geochemical and geophysical anomalies on the Dalton Project. Drilling intersected sulphide mineralization and a number of quartz veins, though, no significant gold mineralization was detected. Based on the lack of significant results, Pelangio will relinquish its option to earn a 90% interest in the Dalton Property but will retain a 10% interest in this project, due to its proximity to the Hollinger Gold Mine.

Ingrid Hibbard, President and CEO commented, "The nature of exploration is that not every prospect will be a success, so it is important that early stage evaluations are done cost-effectively. We will now focus our Ontario exploration efforts with follow up phase 2 priority target drilling at our Grenfell property where we had a major success in early 2020. The best drill hole intercepts from our spring 2020 program at Grenfell returned 314 g/t gold over 1.74 m (uncut) including a higher grade section which assayed 1810 g/t gold over 0.3 m in hole 4, as well as a broader interval of 2.5 g/t gold over 26 m (including 9.39 g/t gold over 3m) in hole 5. (Reference Press Release March 1, 2020). Given the success of the spring drill program at Grenfell, we look forward to the start of our follow up drill program in mid-September.

Grenfell Project

Pelangio's highly prospective Grenfell Project is comprised of 38 mining cells and 8 leased claims covering an area of approximately 6.7 km2, located 10 km northwest of the Town of Kirkland Lake Ontario. (see Map 1, Grenfell Project Property Geology).

Following the completion of the March of 2020 spring drilling program, a review was conducted on a number of targets in the vicinity of the old mine workings in order to outline the phase 2 drilling program. Pelangio anticipates commencing its Grenfell exploration in mid September 2020.

The priority targets (see Map 2) to be tested in the phase 2 program are as follows:

Further evaluation of the strike extension of the northwesterly trending No.6 Vein system. Pelangio's recent drilling from hole 4 returned 2.50 g/t gold over 26 m (including 9.39 g/t gold over 3 m) and hole 5 assayed 314 g/t gold over 1.74 m (uncut).
Drilling is also planned to test the intersection of the No.6 Vein and No.1 vein for a potential mineralized chute along the plane of intersection of the veins. Historical drifting and sampling on the 250 level on the former mine demonstrated that the No.1 Vein averaged 0.2 oz/ton gold over a width of 3 feet for a strike length of 180 feet. A surface bulk sample from a trench on the No.1 Vein allowed for the extraction of 21.7 tons grading 0.456 oz/ton gold.
Very limited drilling is known to have been conducted on the No.1 vein despite extremely encouraging sampling results as documented above. A hole is planned to confirm the values on one of the higher grade portions of the No.1 vein documented in the historical mine level plans.
Historical mine plans on the 250 level have shown two other north northwesterly trending structures in a very similar orientation to the No.6 vein. (see Map 2). These structures have been designated as the Central Target and the Shea Vein. Mine plans and historical reports have documented significant gold mineralization associated with these structures. A historical hole on the Shea Vein returned 0.41 oz/ton gold over 3 feet. Drilling will be conducted on the two targets to test for both potential high grade mineralization as well as broad mineralized wall rock intercepts similar to that found on the No. 6 Vein.

Note: Historical intercepts quoted from a J. Londry P. Eng; Report on the John Sirola Property, Grenfell Township, 1985

GRENFELL DRILL HOLE LOCATION DATA

HOLE NO.

EASTING

NORTHING

AZIMUTH

DIP (Degrees)

LENGTH (m)

4

560318

5336214

198 degrees

-47

60.00

5

560318

5336214

198 degrees

-60

125.50

GRENFELL SIGNIFICANT ASSAY INTERCEPTS

HOLE NO.

FROM

TO

METERS

G/T Au

G/T AU (CUT)

G/T Au (UNCUT)

**4

14.00

15.00

1.00

3.73

**4

19.00

45.00

26.00

2.50

includes

26.00

45.00

19.00

3.18

29.00

45.00

16.00

3.23

37.50

45.00

7.50

4.81

37.50

40.50

3.00

9.39

**5

33.00

59.00

26.00

1.32

33.00

59.00

26.00

21.80

Includes

36.26

38.00

1.74

7.95

36.26

38.00

1.74

314.00

includes

36.26

36.56

0.30

1810.00

Notes:

i) **Denotes intervals reported in previous press release March 1, 2020

ii) Intervals shown as cut with high-grade assays over 34.28571 g/t Au were cut to 34.28571 g/t Au

iii) All intervals shown in the accompanying tables are core lengths as the estimated true width of the zone cannot be determined at this time

Map 1: Grenfell Project Property Geology

Map 2: Composite Surface and 250 Level Plan

Qualified Person

Mr. Kevin Filo, P.Geo. (Ontario), is a qualified person within the meaning of National Instrument 43-101. Mr. Filo approved the technical data disclosed in this release.

About Pelangio

Pelangio acquires and explores world-class gold belt land packages in Canada and Ghana, West Africa. Its key properties in Ontario, Canada, are the Grenfell property, located 10 km from Kirkland Lake, and the Dome West property, situated some 800 meters from the Dome Mine in Timmins. In Ghana, the Company is exploring its two 100% owned camp-sized properties: the 100 km2 Manfo Property, the site of seven near-surface gold discoveries, and the 284 km2 Obuasi Property, located 4 km on strike and adjacent to AngloGold Ashanti's prolific high-grade Obuasi Mine. See www.pelangio.com for further detail on all Pelangio's properties.

For additional information, please visit our website at www.pelangio.com, or contact:

Ingrid Hibbard, President and CEO
Tel: 905-336-3828 / Toll-free: 1-877-746-1632 / Email: info@pelangio.com

Forward Looking Statements

Certain statements herein may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements or information appear in a number of places and can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate" or "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information include statements regarding the Company's ability to complete the planned work programs, the Company's strategy of acquiring large land packages in areas of sizeable gold mineralization, the Company's plans to follow-up on previous work, and the Company's exploration plans. With respect to forward-looking statements and information contained herein, we have made numerous assumptions, including assumptions about the state of the equity markets. Such forward-looking statements and information are subject to risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Such risks include the changes in equity markets, share price volatility, volatility of global and local economic climate, gold price volatility, political developments in Ghana, and Canada, increases in costs, exchange rate fluctuations, speculative nature of gold exploration, including the risk that favourable exploration results may not be obtained, and other risks involved in the gold exploration industry. See the Company's annual and quarterly financial statements and management's discussion and analysis for additional information on risks and uncertainties relating to the forward-looking statement and information. There can be no assurance that a forward-looking statement or information referenced herein will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Also, many of the factors are beyond the control of the Company. Accordingly, readers should not place undue reliance on forward- looking statements or information. We undertake no obligation to reissue or update any forward-looking statements or information except as required by law. All forward-looking statements and information herein are qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Pelangio Exploration Inc.

ReleaseID: 603378

Live video presentation by Chairman and CEO Mark Jensen on Thursday, September 3 at 2:20 PM ET, and virtual 1 on 1 meetings for interested attendees

FISHERS, IN / ACCESSWIRE / August 26, 2020 / American Resources Corporation (NASDAQ:AREC) ("American Resources" or the "Company"), a supplier of raw materials to the rapidly growing global infrastructure marketplace, announced today that Mark Jensen, Chairman and CEO of American Resources Corporation will present at The LD 500 investor conference on Thursday, September 3, 2020 at 2:20 PM ET.

As part of his live video presentation, Mr. Jensen will provide an overview of American Resources' business strategy that has begun to disrupt the industry, as well as discuss how the Company is well-positioned for a surge in global infrastructure initiatives as economies recover post COVID-19.

A live video webcast of the presentation will be available on the conference website, as well as the Investor Relations section of the Company's website (americanresourcescorp.com). A webcast replay will be available two hours following the live presentation and will be accessible for one year.

In addition to the presentation, management will be available for one-on-one meetings during the virtual event. To schedule a one-on-one with management, interested parties may submit a request through the conference website or contact the conference coordinator. For more information about the conference, please visit: ld500.ldmicro.com.

About American Resources Corporation
American Resources Corporation is a supplier of high-quality raw materials to the rapidly growing global infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking. American Resources has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon deposits are concentrated.

American Resources has established a nimble, low-cost business model centered on growth, which provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure market while also continuing to acquire operations and significantly reduce their legacy industry risks. Its streamlined and efficient operations are able to maximize margins while reducing costs. For more information visit americanresourcescorp.com or connect with the Company on Facebook, Twitter, and LinkedIn.

About LD Micro
Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Special Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation's control. The words "believes", "may", "will", "should", "would", "could", "continue", "seeks", "anticipates", "plans", "expects", "intends", "estimates", or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved.

PR Contact:
Precision Public Relations
Matt Sheldon
917-280-7329
matt@precisionpr.co

Investor Contact:
JTC Team, LLC
Jenene Thomas
833-475-8247
AREC@jtcir.com

Company Contact:
Mark LaVerghetta
317-855-9926 ext. 0
Vice President of Corporate Finance and Communications
investor@americanresourcescorp.com

SOURCE: American Resources Corporation

ReleaseID: 603357

LOS ANGELES, CA / ACCESSWIRE / August 26, 2020 / Envision Solar International, Inc. (NASDAQ:EVSI)(NASDAQ:EVSIW), the leading producer of unique and sustainable infrastructure products for electric vehicle charging, energy security and outdoor media, today announced that it will be presenting at the LD 500 investor conference on Wednesday, September 2nd at 8:00 AM PST. Desmond Wheatley, CEO, will be a featured presenter at this virtual event.

Mr. Wheatley will provide an overview of the company's business model and growth strategy and will be available for one-on-one meetings.

"Envision is at a pivotal point in our history. We are debt free and have a very strong balance sheet with several years of operating capital on hand. We have unique and patented products which provide EV charging infrastructure for the best customers in the world like New York City, the State of California, 100 municipalities across the US and companies like Google, Pfizer, Johnson and Johnson and many others," said Desmond Wheatley, Envision's President and CEO. "I am very much looking forward to telling our exciting story at LD Micro."

Register here: https://ld-micro-conference.events.issuerdirect.com/

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space," stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View Envision Solar's profile here: http://www.ldmicro.com/profile/EVSI

Profiles powered by LD Micro – News Compliments of Accesswire

About Envision Solar International, Inc.

Envision Solar, www.envisionsolar.com, produces and sells unique and patented sustainable infrastructure products, for electric vehicle charging, energy security and outdoor media, including the EV ARC™ and the Solar Tree® with EnvisionTrak™ patented solar tracking, SunCharge™ solar Electric Vehicle Charging, ARC™ technology energy storage, and EnvisionMedia™ solar advertising displays.

Based in San Diego, the company produces Made in America products. Envision Solar is listed on the Nasdaq CM under the symbols EVSI and EVSIW. For more information visit www.envisionsolar.com or call (858) 799-4583. Follow us on social media to keep up with the latest news: LinkedIn, Facebook, Twitter, Instagram, and YouTube.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Kathy McDermott
Phone: 858-799-4583
Address: 5660 Eastgate Dr., San Diego, CA
Email: Kathy.McDermott@envisionsolar.com

SOURCE: Envision Solar International, Inc. via LD Micro

ReleaseID: 602842

AUSTIN, TX / ACCESSWIRE / August 26, 2020 / Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will be presenting at the LD 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 1:20 p.m. ET. Rodney Varner, Chairman and Chief Executive Officer of Genprex, will present virtually to an online audience.

Mr. Varner will deliver a Company overview and provide updates on its product pipeline, including its lead drug candidate, GPX-001, which received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for use in combination with AstraZeneca's Tagrisso® in late stage lung cancer patients with EGFR mutations whose tumors progress on Tagrisso. Mr. Varner will also provide an overview of the Company's preclinical diabetes gene therapy candidate that may have the potential to cure Type 1 and Type 2 diabetes.

The presentation will be webcast live and available for replay on the LD 500 conference website here and via the investor relations section of the company's website at Genprex.com.

Event: The LD 500 Virtual Conference

Presentation Date: Tuesday, September 1, 2020

Presentation Time: 1:20 p.m. ET – Track 2

Registration Link: https://ld-micro-conference.events.issuerdirect.com/

Webcast Link: https://bit.ly/31b1i20

The LD 500 will take place September 1-4, 2020 and will feature some of the most prominent companies in the micro-cap world, alongside interviews and keynotes with small-cap leaders.

View Genprex's LD 500 profile here: https://bit.ly/2CHzOrt

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company's web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company's future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Genprex, Inc.
(877) 774-GNPX (4679)

Investor Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
investors@genprex.com

Media Contact
Genprex Media Relations
Kalyn Dabbs
(877) 774-GNPX (4679) ext. #3
media@genprex.com

SOURCE: Genprex, Inc.

ReleaseID: 603393

Cyren Inbox Security positioned in emerging CAPES segment

MCLEAN, VA / ACCESSWIRE / August 26, 2020 / Cyren (NASDAQ:CYRN), a provider of email security and threat intelligence solutions, announced today that it has been included in Forrester's Q3 2020 Now Tech report on Enterprise Email Security Providers.

Forrester's Now Tech report highlights traditional and next generation vendors who provide email security solutions to global enterprises. The report is targeted at CIOs, CISOs, and IT organizations who are looking to improve their security posture against email-borne attacks, including phishing, business email compromise (BEC), and to protect their corporate employees, assets and brand.

The report highlights traditional enterprise email security vendors, such as secure email gateways, email infrastructure providers, email authentication providers, but also introduces a new category of email security solutions which Forrester calls "Cloud-native API-enabled email security" (CAPES). CAPES solutions are highlighted for their ease of use cloud email integration, superior phishing detection, BEC and spoofing protection. Cyren Inbox Security is an innovative, next generation email security solution in this new category.

"Forrester is clearly a very influential research and advisory firm and their report highlights phishing as one of the biggest email security threats organizations face today," said Lior Kohavi, Cyren's Chief Strategy Officer. "We know firsthand that many enterprises are struggling with the problem of phishing in Microsoft 365, and this report helps CISOs identify vendors with unique solutions like Cyren that can detect phishing attacks and provide automated response and remediation."

Launched in April, Cyren Inbox Security has already been deployed by a number of enterprise customers. One such customer is Technion, the Israel Institute of Technology, where Cyren Inbox Security was selected to protect 3,000 business users and up to 40,000 educational user inboxes. "Despite having other Office 365 email security in place, we were still getting impacted by phishing emails, so we chose the cloud-native Cyren Inbox Security to help protect our users," said Moshe Glickstein, Chief Information Security Officer at Technion. "In addition to automated phishing detection, Cyren also provides crowd sourcing that enables our users to report new phishing emails and the automatic remediation allows us to clean those emails from every inbox that was infected. Cyren offers unique capabilities that traditional secure email gateways just don't have."

Cyren Inbox Security can be provisioned on any Microsoft 365 account in a matter of minutes. For more details on CIS features and benefits, to request a quote or to start a free 30 day trial, please visit https://www.cyren.com/inbox-security-free-trial.

About Cyren:

More than 1.3 billion users around the world rely on Cyren's cloud security solutions to protect them against cyber-attacks every day. Powered by the world's largest security cloud, Cyren (NASDAQ: CYRN) delivers fast time-to-protection with embedded threat detection, threat intelligence and email security solutions. Learn more at www.cyren.com.

Blog: http://blog.cyren.com
Facebook: www.facebook.com/CyrenWeb
LinkedIn: www.linkedin.com/company/cyren
Twitter: www.twitter.com/CyrenInc

Company Contact
Mike Myshrall, CFO
Cyren
+1.703.760.3320
mike.myshrall@cyren.com

SOURCE: Cyren Ltd. via EQS Newswire

ReleaseID: 603317

TORONTO, ON / ACCESSWIRE / August 26, 2020 / Gratomic Inc. ("GRAT" or the "Company") (TSXV:GRAT)(OTC PINK:CBULF)(FRANKFURT:CB81) (WKN:A143MR) wishes to announce that its anticipated custom equipment order from China has been safely received ahead of schedule and is currently on site at the Walvis Bay Port in Namibia. This equipment is required for the completion of its Aukam Graphite Mine processing plant construction.

The various components including thickener tanks, cyclone, filter press and chipper, rotary dryer and various additional pieces required for facility completion will be inspected, loaded, and shipped to the Aukam property via trucking service upon clearing customs.

The early arrival has no impact on the Company's prior construction schedule as preparations are currently meeting Gratomic's previously scheduled timelines.

About Gratomic Inc.

Gratomic is a materials company focused on mine to market commercialization of graphite products and components for a range of mass market products. The Company currently holds two off-take purchase agreements for graphite product sourced from the Aukam facility. One agreement is with TODAQ and the other is with Phu Sumika. The Company is listed on the TSX Venture Exchange under the symbol GRAT.

For more information: visit the website at www.gratomic.ca or contact:

Arno Brand at abrand@gratomic.ca or 416 561-4095

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

FORWARD LOOKING STATEMENTS:

This press release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com).

SOURCE: Gratomic Inc.

ReleaseID: 603412

Company to Highlight its Goal of $10M Year-over-Year Adjusted EBITDA Improvement Despite COVID-19 and Provide an Update on its Hydrogen Product Development

VAN NUYS, CA / ACCESSWIRE / August 26, 2020 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that it will be presenting at the LD 500 investor conference on Wednesday, September 2, 2020, at 11:00 AM PT / 2:00 PM ET. Darren Jamison, President and CEO of Capstone Turbine Corporation, will be presenting to a live virtual audience.

"I look forward to presenting to the investment community our plans to improve our adjusted EBITDA $10M year-over-year by leveraging our margin expansion initiatives, high reoccurring revenue aftermarket business, and expanding our long-term rental fleet despite the tremendous economic and public health impacts caused by COVID-19," said Darren Jamison, President and Chief Executive Officer of Capstone Turbine.

"In addition, I look forward to discussing the recent progress of our hydrogen product development efforts with the U.S. Department of Energy's Argonne National Laboratory, as there is a broad global initiative to decarbonize electricity generation through renewable natural gas, or RNG, by blending natural gas and hydrogen in existing pipelines," added Mr. Jamison.

Darren Jamison is scheduled to present on Wednesday, September 2, 2020, at 11:00 AM PT/2:00 pm ET. The presentation material will be made available on the Company's website, www.capstoneturbine.com, under the Investor Relations section.

Darren Jamison, along with Eric Hencken, Chief Financial Officer and Chief Accounting Officer of Capstone, will be available for one-on-one meetings during the conference dates. Qualified institutional investors interested in scheduling a one-on-one meeting with Capstone's management team are encouraged to register here: https://ld500.ldmicro.com/, or contact cpst@integra-ir.com

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space," stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View Capstone Turbine's profile here: http://www.ldmicro.com/profile/CPST

Profiles powered by LD Micro – News Compliments of Accesswire

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ: CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, via our direct sales team, as well as our global distribution network. Capstone provides scalable solutions from 30 kWs to 10 MWs that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects.

For customers with limited capital or short-term needs, Capstone offers rental systems, for more information, contact: rentals@capstoneturbine.com. To date, Capstone has shipped nearly 10,000 units to 83 countries and in FY20, saved customers an estimated $219 million in annual energy costs and 368,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, Facebook and YouTube.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is LD Micro's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 603410

BREMEN, IN / ACCESSWIRE / August 26, 2020 / Digger Specialties, Inc. (DSI), the leading supplier of aluminum railing in the U.S. marketplace, is announcing the immediate availability of Montego II as an extension of the Westbury® Aluminum Railing product line. This elegant railing combines the distinctive curved baluster of the Montego design with the addition of a third rail that further enhances the designer appearance of the Montego II railing system.

Westbury® Montego II railing is available in 12 standard colors in smooth and textured finishes. Custom colors are available by special order. The railing system is available in 36 and 42 inch heights and comes in both straight and stair section lengths from 4 to 8 feet. Radius sections are also available by special order.

Westbury® Aluminum Railing is available in a wide variety of designs that elevate the outdoor living experience. All Westbury® railing systems incorporate a proprietary 10 step powder coating process which provides a long-lasting colorfast finish. Additionally, Westbury® railing systems come with a Lifetime Limited Warranty and offer the durability and low maintenance of aluminum railing for a carefree outdoor lifestyle. "Westbury® Montego ll railing is a premier railing system offering aesthetic and performance advantages unmatched by competitors' products," said Larry G. Boyts, DSI's Vice President of Sales and Marketing.

Information about Westbury® Montego II and other DSI products can be obtained by visiting diggerspecialties.com. For a list of dealers and distributors of Westbury® Aluminum Railing products, including Montego II click on the Where to Buy tab of DSI's website.

DSI is an industry leading manufacturer of aluminum and vinyl railing, aluminum and vinyl fencing, aluminum, composite, and fiberglass architectural columns, and deck lighting.

Contacts

Mary Kittrell
Marketing Manager
Work: 800-446-7659 Ext. 318
mkittrell@diggerspecialties.com

SOURCE: Digger Specialties, Inc.

ReleaseID: 602823

MIAMI, FL / ACCESSWIRE / August 26, 2020 / AllStar Health Brands Inc. (OTC PINK:ALST) a specialty pharmaceutical and nutritional supplements company and TPT Global Tech a technology and solutions company are pleased to announce signing a Non Exclusive Distribution Agreement for Canada and US to add to the existing Non-Exclusive Distribution Agreement for Mexico and other Latin American countries.

"We are very pleased to announce the expansion of our initial non-exclusive partnership agreement to now include Canada and the US. AllStar Health Brands' goal is to work with TPT Medtech for both the geographic expansion of the QuikLAB modules within the US and Canada and also offer the best testing technologies within the QuikLAB modules. Both companies have a shared vision to make one-stop, mass testing for Covid-19, a near-term reality in the Americas," stated Dr. Daniel Bagi, President of AllStar.

AllStar believes that given the high Covid-19 infection rates around the world, and the ability to set up the QuikLAB testing modules at almost any location, the QuikLAB option may be part of the solution in combating the effects of this pandemic.

The QuikLAB testing modules offer a fast, complete testing option, at a rapid throughput, – up to 50 tests/hour, using either the PCR or antibody tests or both currently available on the market. The goal is to provide results within minutes to a few short hours, so appropriate treatment or isolation protocols can be recommended based on the results of the testing."

AllStar plans to provide several options for FDA, EUA-approved rapid Covid-19 anti-body tests, and PCR tests for the TPT Medtech QuikLab modules.

About AllStar Health Brands Inc.:

AllStar Health Brands Inc. is a Nevada Corporation established in 2017, and headquartered in Miami, Florida. AllStar is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select products, including medical devices, nutritional supplements, over the counter remedies and medicines all across the Americas and Europe. AllStar's goal is to bring additional products to the market and provide new, innovative options for better health and wellbeing.

For more information, please contact Investor Relations at (305) 423 7028.

About TPT Global Tech Inc:

TPT Global Tech Inc. (TPTW), based in San Diego, California, is a technology-based company with divisions providing telecommunications, medical technology, and product distribution, media content for domestic and international syndication as well as technology solutions. TPT Global Tech offers Software as a Service (SaaS), Technology Platform as a Service (PAAS), Cloud-based Unified Communication as a Service (UCaaS). It offers carrier-grade performance and support for businesses over its private IP MPLS fiber and wireless network in the United States. TPT's cloud-based UCaaS services allow businesses of any size to enjoy all the latest voice, data, media, and collaboration features in today's global technology markets. TPT Global Tech also operates as a Master Distributor for Nationwide Mobile Virtual Network Operators (MVNO) and Independent Sales Organization (ISO) as a Master Distributor for Pre-Paid Cellphone services, Mobile phones Cellphone Accessories and Global Roaming Cellphones.

Safe Harbor Statement
Statements about the Company's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties, and assumptions, including the risks and uncertainties, noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing, and general economic risks and uncertainties.

SOURCE: Allstar Health Brands, Inc.

ReleaseID: 603297

Data supports a differentiated gp96-based COVID-19 vaccine that induces systemic and tissue-specific (lung) memory CD8+ T cells
Gp96-based vaccine generates tissue-resident memory CD8+ T cells that may be instrumental in eradicating SARS-CoV-2 infected cells
Tissue specific memory CD8+ T cells potentially important for compromised patient populations

DURHAM, NC / ACCESSWIRE / August 26, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced publication of positive preclinical COVID-19 results in bioRxiv, which is available at: https://www.biorxiv.org/content/10.1101/2020.08.24.265090v1.

Publication highlights for Heat's gp96 based COVID-19 vaccine (gp96-Ig-S):

Significantly increases the frequency of systemic and tissue-specific CD8+ T-cells by conferring cellular immunity that is essential against any viral infection, including SARS-CoV-2
Primes potent effector memory CD8+ T cell responses and tissue resident memory CD8+ T cells localized in lung which are essential in protection against respiratory virus infection
Elicits a robust immune response directed against the Spike protein of SARS-CoV-2, generating both helper CD4+ T-cells that aide in antibody production, as well as virus killing cytotoxic CD8+ T cells
Induces the secretion of cytokines (IFN-gamma, IL-2, TNF-alpha) from CD8+ and CD4+ T cells in both the spleen and lungs
Induces high frequencies of S-protein specific (against S1 and S2 epitopes) CD8+ T cells in the respiratory airways, the predominant site of viral infection

Studies in COVID-19 patients with moderate or asymptomatic infection indicate that the expansion of memory CD8+ T cells directed at immunodominant epitopes on S protein may be important, including tissue resident CD8+ T cells that localize in high numbers in the lung tissue to protect against infection (1,2,3). The preclinical data demonstrates that Heat's vaccine achieves this objective with tissue resident memory CD8+ T cells that localize in lung tissue. The generation of a durable cellular immune response driven by memory CD8+ T cells may protect against re-infection. Heat's vaccine is designed to prophylactically "train" the immune system to induce this response in patients and should be especially effective in those individuals most prone to severe infection, such as the elderly, individuals with relevant comorbidities or other patients who are immuno-suppressed.

Natasa Strbo, MD, DSc, Assistant Professor of Microbiology and Immunology at the University of Miami Miller School of Medicine and co-developer of Heat's gp96 platform, commented, "Vaccines that can induce SARS-CoV-2 specific CD8+ T cells that home in to the airway epithelium are needed to effectively mount an immune response against SARS-CoV-2. Our latest publication demonstrates the importance of tissue resident memory CD8+ T cells triggered by our vaccine in protecting against infection."

Jeff Wolf, Chief Executive Officer of Heat, commented, "We believe that these results are a powerful reinforcement that this platform represents a unique and relevant paradigm for novel vaccine development, capable of inducing cellular immune responses in epithelial tissues such as the lungs. This publication demonstrates the potential utility and versatility of our vaccine platform to address SARS-CoV-2, relevant mutations and other pathogens of interest."

1. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4 (+) and CD8 (+) T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients. bioRxiv. 2020. Epub 2020/06/25. doi: 10.1101/2020.06.05.134551. PubMed PMID: 32577665; PubMed Central PMCID: PMCPMC7302222.

2. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin J-B, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. bioRxiv. 2020.

3. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842-4. doi: 10.1038/s41591-020-0901-9. PubMed PMID: 32398875.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

For more information, please visit: www.heatbio.com, and also follow us on Twitter.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as Heat's vaccine prophylactically "training" the immune system to induce this response in patients and being especially effective in those individuals most prone to severe infection, such as the elderly, individuals with relevant comorbidities or other patients who are immuno-suppressed, the results being a powerful reinforcement that this platform represents a unique and relevant paradigm for novel vaccine development, capable of inducing cellular immune responses in epithelial tissues such as the lungs and the potential utility and versatility of Heat's vaccine platform to address SARS-CoV-2, relevant mutations and other pathogens of interest. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat's vaccine platform to provide protection against COVID-19, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

ReleaseID: 603382